49
Participants
Start Date
April 30, 2012
Primary Completion Date
September 30, 2013
Study Completion Date
October 31, 2013
Single Ascending Dose (SAD) Cohorts GS-9620
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Multiple Ascending Dose (MAD) Cohorts
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
Auckland Clinical Studies, Grafton
Nepean Hospital, Kingswood
Monash University, Department of Medicine, Clayton
Royal Brisbane and Women's Hospital, Herston
Royal Perth Hospital, Nedlands
Weill Cornell Medical College, New York
CRI Worldwide, LLC, Philadelphia
University Hospitals Case Medical Center, Cleveland
Henry Ford Health System, Detroit
Kansas City Gastroenterology and Hepatology, Kansas City
Tulane University Health Sciences Center, New Orleans
Baylor College of Medicine, Houston
University of Utah, Salt Lake City
Mayo Clinic Hospital, Phoenix
University of California Antiviral Research Center (AVRC), San Diego
West Coast Clinical Trials, LLC, Costa Mesa
Indiana University Medical Center, Indianapolis
Beth Israel Deaconess Medical Center, Boston
University of Calgary, Heritage Medical Research Center, Calgary
University of Alberta Hospital, Edmonton
Algorithme Pharma, Inc., Montreal
Asan Medical Center, Seoul
Seoul National University Hospital, Seoul
Lead Sponsor
Gilead Sciences
INDUSTRY